Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Gnmsf crawled time : 16:20 save search
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
Published: 2023-10-22 (Crawled : 16:20) - globenewswire.com
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
| Email alert
Add to watchlist
SGEN | $228.74 0.1% 20M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | News | $290.34 3.83% 340
|
Health Technology
| Email alert
Add to watchlist
tivdak cancer global trial
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
Published: 2022-06-11 (Crawled : 16:20) - globenewswire.com
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
| Email alert
Add to watchlist
GNMSF | News | $290.34 3.83% 340
|
Health Technology
| Email alert
Add to watchlist
cd20 duobody symposium trial results
Updated Data for Janssen's Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-06-05 (Crawled : 16:20) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
| Email alert
Add to watchlist
GNMSF | News | $290.34 3.83% 340
|
Health Technology
| Email alert
Add to watchlist
treatment
New Clinical and Real-World Data Support Use of DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
Published: 2021-12-11 (Crawled : 16:20) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | News | $290.34 3.83% 340
|
Health Technology
| Email alert
Add to watchlist
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
| Email alert
Add to watchlist
darzalex
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.